메뉴 건너뛰기




Volumn 18, Issue 5, 2016, Pages 533-536

Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide

Author keywords

Anti drug antibody; Dulaglutide; Type 2 diabetes

Indexed keywords

DRUG ANTIBODY; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; NEUTRALIZING ANTIBODY; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; NEW DRUG;

EID: 84959548145     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12640     Document Type: Letter
Times cited : (24)

References (19)
  • 1
    • 84993811110 scopus 로고    scopus 로고
    • Immunogenicity and other problems associated with the use of biopharmaceuticals
    • Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Saf 2011; 2: 113-128.
    • (2011) Ther Adv Drug Saf , vol.2 , pp. 113-128
    • Tovey, M.G.1    Lallemand, C.2
  • 2
    • 0035760892 scopus 로고    scopus 로고
    • Thrombocytopenia caused by the development of antibodies to thrombopoietin
    • Li J, Yang C, Xia Y etal. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241-3248.
    • (2001) Blood , vol.98 , pp. 3241-3248
    • Li, J.1    Yang, C.2    Xia, Y.3
  • 3
    • 84962971532 scopus 로고    scopus 로고
    • Accessed 8 July
    • Guidance for Industry Immunogenicity Assessment for Therapeutic Protein Products. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338856.pdf. Accessed 8 July 2015.
    • (2015)
  • 4
    • 79953032228 scopus 로고    scopus 로고
    • LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects
    • Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab 2011; 13: 434-438.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 434-438
    • Barrington, P.1    Chien, J.Y.2    Tibaldi, F.3    Showalter, H.D.4    Schneck, K.5    Ellis, B.6
  • 5
    • 77952756104 scopus 로고    scopus 로고
    • Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein
    • Glaesner W, Vick AM, Millican R etal. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 2010; 26: 287-296.
    • (2010) Diabetes Metab Res Rev , vol.26 , pp. 287-296
    • Glaesner, W.1    Vick, A.M.2    Millican, R.3
  • 6
    • 0035859982 scopus 로고    scopus 로고
    • From genome to vaccine: in silico predictions, ex vivo verification
    • De Groot AS, Bosma A, Chinai N etal. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 2001; 19: 4385-4395.
    • (2001) Vaccine , vol.19 , pp. 4385-4395
    • De Groot, A.S.1    Bosma, A.2    Chinai, N.3
  • 7
    • 84930074468 scopus 로고    scopus 로고
    • Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
    • Blonde L, Jendle J, Gross J etal. Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. Lancet 2015; 385: 2057-2066.
    • (2015) Lancet , vol.385 , pp. 2057-2066
    • Blonde, L.1    Jendle, J.2    Gross, J.3
  • 8
    • 84914666192 scopus 로고    scopus 로고
    • Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus
    • Ferdinand KC, White WB, Calhoun DA etal. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension 2014; 64: 731-737.
    • (2014) Hypertension , vol.64 , pp. 731-737
    • Ferdinand, K.C.1    White, W.B.2    Calhoun, D.A.3
  • 9
    • 84962338740 scopus 로고    scopus 로고
    • Efficacy and safety of once weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)
    • Giorgino F, Benroubi M, Sun J-H, Zimmermann AG, Pechtner V. Efficacy and safety of once weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care 2015; 38: 2241-2249.
    • (2015) Diabetes Care , vol.38 , pp. 2241-2249
    • Giorgino, F.1    Benroubi, M.2    Sun, J.-H.3    Zimmermann, A.G.4    Pechtner, V.5
  • 10
    • 84904992244 scopus 로고    scopus 로고
    • Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)
    • Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 2014; 37: 2149-2158.
    • (2014) Diabetes Care , vol.37 , pp. 2149-2158
    • Nauck, M.1    Weinstock, R.S.2    Umpierrez, G.E.3    Guerci, B.4    Skrivanek, Z.5    Milicevic, Z.6
  • 11
    • 84904360390 scopus 로고    scopus 로고
    • Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)
    • Umpierrez G, Povedano ST, Manghi FP, Shurzinske L, Pechtner V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care 2014; 37: 2168-2176.
    • (2014) Diabetes Care , vol.37 , pp. 2168-2176
    • Umpierrez, G.1    Povedano, S.T.2    Manghi, F.P.3    Shurzinske, L.4    Pechtner, V.5
  • 12
    • 79953035319 scopus 로고    scopus 로고
    • The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study
    • Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson JH, Bastyr EJ III. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab 2011; 13: 418-425.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 418-425
    • Umpierrez, G.E.1    Blevins, T.2    Rosenstock, J.3    Cheng, C.4    Anderson, J.H.5    Bastyr, E.J.6
  • 13
    • 84905012167 scopus 로고    scopus 로고
    • Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)
    • Wysham C, Belvins T, Arakaki R etal. Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 2014; 37: 2159-2167.
    • (2014) Diabetes Care , vol.37 , pp. 2159-2167
    • Wysham, C.1    Belvins, T.2    Arakaki, R.3
  • 14
    • 84908331441 scopus 로고    scopus 로고
    • Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study
    • Terauchi Y, Satoi Y, Takeuchi M, Imaoka T. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocr J 2014; 61: 949-959.
    • (2014) Endocr J , vol.61 , pp. 949-959
    • Terauchi, Y.1    Satoi, Y.2    Takeuchi, M.3    Imaoka, T.4
  • 15
    • 84866435806 scopus 로고    scopus 로고
    • Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study
    • Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabet Med 2012; 29: 1260-1267.
    • (2012) Diabet Med , vol.29 , pp. 1260-1267
    • Grunberger, G.1    Chang, A.2    Garcia Soria, G.3    Botros, F.T.4    Bsharat, R.5    Milicevic, Z.6
  • 16
    • 84860250733 scopus 로고    scopus 로고
    • Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment
    • Fineman MS, Mace KF, Diamant M etal. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab 2012; 14: 546-554.
    • (2012) Diabetes Obes Metab , vol.14 , pp. 546-554
    • Fineman, M.S.1    Mace, K.F.2    Diamant, M.3
  • 17
    • 84962925548 scopus 로고    scopus 로고
    • Version 15.0. Chantilly, Virginia. March 2012. Accessed 8 July 2015.
    • International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (IHC). Introductory Guide for Standardised MedDRA Queries (SMQs) Version 15.0. Chantilly, Virginia. March 2012. Available from URL: http://www.meddra.org/sites/default/files/guidance/file/smq_intguide_15_0_english.pdf. Accessed 8 July 2015.
    • Introductory Guide for Standardised MedDRA Queries (SMQs)
  • 18
    • 84903597970 scopus 로고    scopus 로고
    • Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations
    • Shankar G, Arkin S, Cocea L et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J 2014; 16: 658-673.
    • (2014) AAPS J , vol.16 , pp. 658-673
    • Shankar, G.1    Arkin, S.2    Cocea, L.3
  • 19
    • 84874434023 scopus 로고    scopus 로고
    • The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial
    • Rosenstock J, Balas B, Charbonnel B etal. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care 2013; 36: 498-504.
    • (2013) Diabetes Care , vol.36 , pp. 498-504
    • Rosenstock, J.1    Balas, B.2    Charbonnel, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.